Details for New Drug Application (NDA): 217469
✉ Email this page to a colleague
The generic ingredient in VEVYE is cyclosporine. There are eighteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
Summary for 217469
| Tradename: | VEVYE |
| Applicant: | Harrow Eye |
| Ingredient: | cyclosporine |
| Patents: | 5 |
Pharmacology for NDA: 217469
| Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
Medical Subject Heading (MeSH) Categories for 217469
Suppliers and Packaging for NDA: 217469
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469 | NDA | Harrow Eye, LLC | 82667-900 | 82667-900-02 | 1 BOTTLE, DROPPER in 1 CARTON (82667-900-02) / 2 mL in 1 BOTTLE, DROPPER |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;OPHTHALMIC | Strength | 0.1% | ||||
| Approval Date: | May 30, 2023 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | May 30, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 22, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Nov 20, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
Complete Access Available with Subscription
